Older patients are generally not included in Phase 1 clinical trials despite being the population group who use the largest number of prescription medicines. Physiologically based pharmacokinetic (PBPK) modelling provides an understanding of the absorption and disposition of drugs in older patients. In this review, PBPK models used for the prediction of absorption and exposure of drugs after parenteral, oral and transdermal administration are discussed. Comparisons between predicted drug pharmacokinetics (PK) and observed PK are presented to illustrate the accuracy of the predictions by the PBPK models and their potential use in informing clinical trial design and dosage adjustments in older patients. In addition, a case of PBPK modelling of a bioequivalence study on two controlled release products is described, where PBPK predictions reproduced the study showing bioequivalence in healthy volunteers but not in older subjects with achlorhydria, indicating further utility in prospectively identifying challenges in bioequivalence studies.
Introduction
Despite being the population group that receive the largest number of drug prescriptions annually, older patients are generally not included in Phase 1 clinical trials during drug development. Complex pathophysiology, variability in organ function and the presence of co-medication are some of the factors that may account for the exclusion of older patients from clinical pharmacokinetic (PK) studies. Drug dose regimens used in the older patients are frequently determined by trial and error or extrapolated from doses relevant to young adults. Such extrapolations may not be appropriate since the scaling factors like age and weight that are used for extrapolation may not be linearly related to the PK variability associated with the older patient [1] . Considerable variability in drug response exists in the older patient [2, 3] , making dose selection very complex. In the absence of well-designed and appropriate clinical trials focused on the older patient, modelling and simulation offers a good tool to understand PK and pharmacodynamic (PD) variability and their impact on drug doses in this population.
Systems biology endeavours to quantify the contributions of the molecular elements of a biological system to assess their interactions and to integrate that information into models that can provide predictive hypotheses to explain the behaviours of the biological system when subjected to changes and different environmental exposures [4] . Systems pharmacology, a science pertinent to the study of drugs, has been described as a marriage between physiologically based pharmacokinetic (PBPK) modelling and in vitro-in vivo extrapolation (IVIVE) techniques under the umbrella of systems biology [5] . PBPK models encompass the principles of systems biology and constitute a modelling approach that describes the absorption and disposition of drug molecules as well as their biological and physiological drivers. An increased understanding of these physiological and biological drivers and their interactions with different drug molecules and formulations provide valuable insights into how drugs will behave in healthy volunteers and other population groups such as patients with diseases or extremes of age [6] . As illustrated in Fig. 1 , based on the systems pharmacology approach, PBPK models constitute three essential components. These include biological and physiological factors relevant to the human body (systems related properties such as age, weight, sex, genetics, organ size and blood flow, enzyme abundance and activity, ethnicity etc.), drug related properties (e.g. physiochemical properties that determine permeability through membranes, protein binding, binding to enzymes and transporters etc.) and the study trial design (dose, frequency of dosing, duration of the study etc.). These components are combined and integrated mechanistically, enabling the simulation and prediction of PK/PD parameters and concentration-time and response-time profiles in virtual populations. Considering the progressive biological and physiological changes that accompany the process of aging, together with co-existing diseases and polypharmacy, IVIVE-linked PBPK models are ideally suited to predict the impact of these variables on the absorption and disposition of drugs in older patients. While PBPK modelling has the potential for mapping inter-individual variability in drug concentrations that reach the plasma following delivery by different Fig. 1 . Schematic representation of the systems pharmacology approach to population pharmacokinetic/pharmacodynamic modelling. administration routes, it carries the added capability of predicting drug concentrations in the different organs in the body, which may be related to the site of action of the drug. A further advantage of using PBPK models is that 'what if' scenarios can be simulated to obtain information on the 'worst case' scenarios that cannot normally be tested in a clinical trial but may emerge after the drug is marketed.
Depending on the application, the structure of the PBPK model may be simple (minimal PBPK model) such as that shown in Fig. 2A (where all the tissues besides the liver and gut are lumped together as a single compartment) or more complex (whole body PBPK model), where all the major tissue compartments in the body are represented (Fig. 2B ). Drug movement between the different tissues/organs are simulated using differential equations. Each organ compartment can be a simple static compartment with passive permeability or more mechanistic, where variables such as transporters, metabolizing enzymes and differential drug permeability are considered. Detailed descriptions of PBPK models, data requirements for effective PBPK models, differential equations used and applications in drug development and regulatory submissions have been extensively reviewed [5] [6] [7] [8] [9] [10] [11] [12] . In this paper, applications of PBPK models to evaluate drug absorption, distribution, metabolism and excretion (ADME) in older subjects, following administration parenterally, orally and topically are presented. We also briefly discuss the role of formulation-related issues regarding variability and how they may interplay with age. The latter may be considered as re-visiting the wisdom of conducting bioequivalence studies in healthy volunteers rather than the patient groups for whom the drug product is intended, especially for drugs with properties such as pH dependent release and dissolution.
Overview of the methods used to predict PK parameters using IVIVE-linked PBPK models
This overview describes the PBPK models available in the Simcyp population based simulator. The brief summary should serve to illustrate how changes in the systems parameters can impact quantitatively on the PK of the drug.
Study Population
Default Simcyp parameter values required for creating a virtual North European Caucasian population (e.g. physiological parameters including liver volume and blood flows, enzyme abundances etc.) have been described previously [13] . Demographics, physiological and anatomical parameter values obtained from extensive literature searches are used to generate each study population, with variability between the subjects in the population. While the North European Caucasian population is the base population within the simulator, parameter changes relevant to other populations, such as Chinese or geriatrics, can be used to generate the special populations.
Prediction of PK

Absorption
Drug delivery from various routes of administration and different dosage forms can be used in the prediction of absorption and disposition of drugs. Oral absorption will be discussed briefly here since this is the most common route for drug delivery. Predictions can be made using a first-order absorption model, a compartmental absorption transit (CAT) model [14] or the advanced dissolution absorption metabolism (ADAM) model [11] .
Bioavailability (F) of orally administered solid dosage forms involves release of the drug from the formulation, dissolution in the biological fluids, passage through the gut wall, and passage through the liver before it reaches the systemic circulation. Consequently, the following three parameters need to be considered: the fraction of the dose that enters the gut wall (fa), the fraction that escapes metabolism in the gut wall and enters the portal vein (F G ), and the fraction that enters the liver and escapes metabolism (F H ). The total bioavailability is the product of these three components (i.e., F = fa × F G × F H ).
When the first-order absorption model is used, clinically observed inputs for the first order absorption rate constant (ka) and fraction absorbed (fa) can be used. Alternatively, these parameters can be predicted from an estimate of in vivo permeability, Peff,man, and the radius of the small intestine (R) [14] , using Eqs. (1) and (2) below: Fig. 2 . A. Minimal physiologically-based pharmacokinetic model with (lower) single adjusting compartment. Q H , Q PV , and Q HA are blood flows in the liver, portal vein, and hepatic artery, respectively; k in and k out are first order rate constants which act on the masses of drug within the systemic compartment and the SAC respectively, alternatively, the inter-compartmental clearance (Q) can be used; IV and PO are intravenous and oral dosing routes respectively; ka is the first order absorption rate constant. B. Whole body physiologically-based pharmacokinetic model. Q H , Q HA , Q PV , Q G , Q T,A and Q T are blood flows in the hepatic vein, hepatic artery, hepatic portal vein, gut and blood flows into and out of the other tissue (T) compartments, respectively; E G and E H are the fractions undergoing first pass metabolism in the gut and liver, respectively; CL R is the renal clearance; fa and ka are the fraction absorbed and the first order absorption rate constant, respectively.
The fraction of drug that escapes first pass metabolism and enters the portal vein (F G ) is influenced by the presence of enzymes and transporters in the gut [15] . F G can be estimated using Eq. (3) [16] , where Q gut is a blood flow parameter, fu gut is the unbound drug fraction in the gut and CLu G,int represents the gut intrinsic clearance:
The fraction avoiding first-pass metabolism in the liver (F H ), can be calculated using Eq. (4), where Q H (hepatic blood flow), fu B (the fraction of drug unbound in blood) and Clu int,H (intrinsic metabolic clearance) are the primary determinants of net hepatic clearance (CL H ):
Fig . 3A illustrates a typical PBPK model for absorption that accounts for the differences in enzyme abundance (e.g. CYP3A4) and transporter abundance (e.g. P-glycoprotein) along the gastrointestinal tract. The model also accounts for other differences such as pH along the different segments. Fig. 3B represents a section of the small intestine, illustrating all the processes that can be simulated using ADAM [17] .
Distribution
Factors such as tissue volumes and plasma:tissue partition coefficients are considered when predicting the volume of distribution of a drug. The following equation is used to predict V ss when using the minimal PBPK model:
Where V is the fractional body volume (L/kg) of a tissue (t), erythrocyte (e), or plasma (p), E:P is the erythrocyte:plasma ratio and P t:p is the partition coefficient for non-adipose and adipose components [18] .
Elimination
Metabolic drug elimination is defined in many physiologically based models using input data on intrinsic clearance (CL int ). This is scaled up based on specific enzyme abundance (CYP in case below), a scaling factor depending on which system is used (e.g. microsomes (MPPGL), hepatocytes etc.) and organ size (usually liver but could be kidney) to give an intrinsic clearance for the whole organ (Eq. (6)).
The whole organ intrinsic clearance is then scaled up using a suitable model, usually the 'well stirred model' incorporating data on fraction of drug unbound in blood (fu B ), the whole organ intrinsic clearance (CL int ) values from all enzyme pathways and organ blood flow (Q H ) (Eq. (7)). The overall metabolic clearance in each organ is then added to the renal, biliary and any additional systemic clearance values to give the overall elimination of the drug.
PBPK modelling in geriatric populations
PBPK models covering the geriatric population have been published previously [19, 20] , and were reported to predict PK parameters for a variety of drugs used in the elderly with reasonable accuracy. Many of the systems parameters, which form an important part of these models, change with age. A brief summary of the main changes likely to give rise to altered drug disposition in the older population is given below. These are included as part of the Simcyp PBPK Geriatric population and it is the development of this model that we concentrate on below. The database of Thompson et al. can be used as a starting point for establishing PBPK for the geriatric population which included those N65 years [21] . The review below mainly focusses on the major determinants of the factors governing drug elimination with mention of other areas relevant to building PBPK models in the geriatric population. For all parameters, only the changes resulting from the normal aging process are included. Whilst it is acknowledged that older patients often develop disease, those with overt renal or hepatic impairment are included in separate PBPK populations (moderate/severe renal impairment or liver cirrhosis Child-Pugh A, B, C) discussed previously [22, 23] .
Demographics
The typical age distribution seen in the elderly population is shown in Fig. 4A . This can be incorporated into PBPK using a Weibull function. Fig. 3 . A. Structure of the ADAM model in which the GI tract is divided into 9 sections with segregated blood flows to each section. The abundance of various enzymes and transporters in each segment varies non-monotonically along the intestine as indicated by the varying intensity of the colour for each section (CYP3A distribution is indicated in purple and P-gp in green). [17] . B. Segment of the small intestine indicating the various processes that can be simulated. [17] .
There is a trend for reduced height with age with the rate of reduction in height increased in older age bands [20] . This is shown Fig. 4B based on Health survey for the UK [24] . To ensure a correlated Monte-Carlo approach body weight should be modelled based on height (Fig. 4C) . This prevents the simulation of physiologically implausible virtual subjects. Similar to height, body weight also tends to decline in the older population with more rapid decline in older age bands.
Absorption
For oral absorption there is conflicting evidence on changes in gastric emptying (GE) and intestinal transit times (ITT) in the elderly, with studies showing both longer and shorter GE and ITT in this age group compared to a young adult group. Consequently, this parameter was left unchanged in the geriatric PBPK population [25, 26] . There is evidence of a 10% increase in the Inter digestive Migrating Motor Complex in subjects in their eight decade compared to young adults. Weighted average was 112.4 min in 82 year olds (n = 25) compared to 102 min in 31 year olds (n = 29) [27, 28] . This could impact on the biliary excretion of drugs and subsequently enterohepatic recirculation in the elderly.
Distribution
There are many organ systems where there is a decline in organ size with age and this has been reviewed in detail by Schlender et al. 2016 [20] . Within a PBPK model, changes to organ blood flows are related to the decline in cardiac output with age [29] [30] [31] . This is shown for cardiac output in males in Fig. 5A with simulated data compared to observed data.
Drug elimination
The main changes to the processes that may alter drug elimination with age and that will need to be incorporated into any geriatric PBPK model are given in the individual sections below.
Metabolism
Various studies have investigated age related changes in CYP enzymes with some conflicting results. Blanco et al. [32] investigated age related changes in microsomal CYP1A2 (ethoxyresorufin), CYP2E1 (ethoxycoumarin), CYP3A4/5 (midazolam) and CYP2C8 (paclitaxel 17α position) and found no age related change in activity between subjects N60 years compared to those N10 to 59 years. Previously Hunt et al. had also demonstrated no change in CYP3A activity in vitro with age (range 27 to 83 years) [33] and also in vivo using the erythromycin breath test between an older (70 to 88 years) compared to a younger age group (20 to 60 years) [34] . In another study the same authors showed no change in CYP2E1 activity over the range of 30 to 75 years [35] . Schmucker et al also demonstrated the absence of significant age differences in the activities and content of human liver monooxygenases [36] . In contrast George et al had shown a negative association between expression of CYP2E1 and CYP3A and older age [37] .
A study by Parkinson et al 2004 investigated the effects of age on CYP activity in human liver microsomes [38] . Data was arranged into three age groups b20 y, 20 to 60 y and N60 y, each age group was composed of a minimum of 19 samples. Only CYPs 1A2, 2D6 and 2E1 were found to be statistically significantly different with older age based on linear regression analysis, however, CYPs 1A2, 2B6, 2C19, 2D6 and 2E1 appeared to decrease N25% whilst CYPs 2A6 and 4A11 appeared to increase N25% between the oldest and youngest groups.
A study of in vivo drug metabolism based around administration of probe drug substrates to children and adolescents b19 years, adults 20 to 64 years and elderly adults N64 years [39] showed a decrease in metabolism of CYP1A2 (caffeine, theophylline), CYP2C9 tolbutamide, phenytoin and ibuprofen), CYP2C19 (amitriptyline and nortriptyline), CYP2E1 (acetaminophen) and CYP3A4 (midazolam, lidocaine and terfenadine) with increasing age. Whilst the suitability of a number of these probe drugs is questionable, a clear trend was observed but in light of other results these observations may have more to do with reducing liver size and blood flow rather than changes in specific enzyme expression and activity. In the final PBPK model no changes were implemented to the expression of CYP enzymes in the geriatric population and the same values as per the North European Caucasian population were used.
Older age is thought to have only a modest, if any, effect on hepatic glucuronidation of certain drugs in vivo [40] , this is in agreement with in vitro data from a number of studies. Herd et al. [41] studied paracetamol glucuronidation (later confirmed as UGTs1A1, 1A9 and 2B15 [42] ) activity in microsomes prepared from livers from individuals aged 44 to 89 years, and there was no significant correlation with age. Parkinson et al. [36] measured UGT activity in hepatocytes prepared from those aged 20 to 60 and those aged N60 years using 4-methylumbelliferone as a probe and found no difference between the groups. Further to this, Court et al. [43] studied age related changes in UGT activity in liver microsomes prepared from 55 individuals aged 5 to 75 years, taking out the paediatric liver samples this left data from 47 individuals N20 years and of these 13 who were N60 years. Using probe substrates, estradiol (UGT1A1), trifluoperazine (UGT1A4), serotonin (UGT1A6), propofol (UGT1A9), zidovudine (UGT2B7) and oxazepam (UGT2B15), again no age related changes in activity were observed between donors N60 and those b60 years. There is no evidence that the expression of UGT enzymes should be altered for the geriatric population in a PBPK model.
Little data exists for effects of older age on other drug metabolizing enzymes, the study by Herd et al. [41] additionally measured paracetamol sulphation from the cytosolic fractions in subjects 40 to 89 years and, similar to glucuronidation, found no correlation with age. A study by Farah et al. [44] measured the rate of acetylation of isoniazid in young adults (20 to 35 years) vs. the elderly (N65 years) and found no difference between the two populations. Finally Woodhouse et al. [45] measured both hepatic glutathione concentration and epoxide hydrolase activity and found no change with age.
Liver size
There is good evidence that liver size decreases with increasing age in the adult population with the decrease becoming more pronounced after 60 years of age [46] [47] [48] [49] [50] [51] , this data is summarized for females in Fig. 5B . The reduced effective liver mass results in a reduced capacity for drug elimination (Eq. (6)). This is matched by biopsy data showing a reduced number of hepatocytes in livers from elderly subjects [34] . The reduced liver size is incorporated into the geriatric population PBPK model.
Liver blood flow
The liver blood flow is defined in the geriatric PBPK model as a fixed percentage of cardiac output and hence is reduced with age, this is in agreement with observed data [52, 53] . The simulated liver blood flow for males and females with some measured data are shown in Fig. 5C . In a study by Wynne et al. there was a significant negative correlation between indocyamine green clearance and apparent liver blood flow and age [52] . The reduction in liver blood flow may result in reduced clearance for particularly intermediate and high extraction drugs in the elderly. Castleden et al. [54] showed a reduced systemic clearance of propranolol in older subject (mean age 78 years) compared to a younger group (mean age 29 years), they also showed higher bioavailability in the elderly due to reduced first-pass metabolism.
Protein binding
There appear to be very little change in plasma albumin concentrations with older age based on observed data [55] [56] [57] this is in agreement with the algorithms already used in the geriatric PBPK model which calculates albumin based on BMI and age. The observed data for older age related changes in alpha-1-acid glycoprotein show either no change [57] or a slight reduction with older age [56] , no change with age for α-1 acid glycoprotein is currently included in the geriatric population PBPK model.
Renal elimination
The age related decline in renal function is well known [58] [59] [60] [61] . The age related changes in glomerular filtration rate (GFR) in geriatric PBPK model are calculated using age related plasma creatinine data derived from the NHANES database [62] using either the Cockcroft-Gault or modified diet in Renal disease equations. The simulated and observed changes in GFR in older age are shown in Fig. 5D .
The magnitude of the changes in system parameters in the geriatric compared to HV populations within a PBPK model are shown in Table 1 . The effects of these changes on the degree of change in the PK of actual and theoretical drugs of different extraction ratio has been predicted by the model and the results are in line with what is expected.
Prediction of clearance and exposure to six drugs in virtual geriatric patients following oral or parenteral administration
Clinical data on the PK of caffeine [64] , desipramine [65] , midazolam [66] , digoxin [67] , warfarin [19] , triazolam [68] and omeprazole [69] in older patients was extracted from the literature. These compounds were available in the Simcyp compound library and literature data comparing the PK in younger and older subjects were available for comparison with predicted data. Initially, availability of clinical data that compares PK in young and older subjects is essential for performance verification of the PBPK models. The Geriatrics model described above was used to simulate the published studies and the predicted clearance and AUC was compared with the clinically observed values. Fig. 6A shows the predicted clearance values relative to the observed clearance and it can be seen that there is acceptable recovery of the observed data by the model. Fig. 6B shows the ratio of the predicted and observed % decrease in clearance between young and elderly patients. All these ratios are ≤1.5 (Fig. 6B) suggesting good recovery of the comparative clinical data between young and elderly subjects. While plasma concentrations in the older subjects were generally higher, some drug concentrations, such as those for midazolam, suggest that lower dosages may be more appropriate in this patient group.
Schlender and co-workers [20] used parenterally administered morphine and furosemide to verify a geriatrics model that they had developed. Satisfactory recovery of the clinical data was reported. These results indicate that both the Geriatrics models were successful in the prediction of exposure of these drugs following oral and parenteral delivery. Following verification of PBPK models, they can be used prospectively to predict differences in drug exposure between young and elderly subjects from different dosage formulations. Such predictions can assist with dosage adjustments in the elderly. Table 1 Summary of changes to system parameters within a geriatric PBPK model resulting in altered ADME and thus predicted PK compared to a healthy volunteer population. 
ADME
PBPK model for topical application
PBPK models are also useful tools allowing for prediction of systemic exposure following dermal administration. Combining information on genetic, physiological and demographic variability with preclinical in vitro data to allow extrapolation to in vivo population pharmacokinetics, the development of databases and models for dermal absorption can be considered as major advancement in the area of pharmaceutical science and drug delivery. A mechanistic dermal absorption model informed by human physiology (e.g. skin layer thickness, lipid contents, blood flow rates, etc.) was developed and integrated into the Simcyp Simulator to predict human dermal absorption of drugs [70] . This model was validated using 5 different diclofenac formulations. The effect of penetration enhancers, site of application, gender and ethnic variations were also incorporated in the simulated clinical trials. Good recovery of the observed drug exposure and population variability was evident in all five validation studies.
An enhanced version of this model is a transient, multi-phase and multi-layer (MPML) mechanistic dermal absorption model (MechDermA). The MPML MechDermA model (as shown in Fig. 7 ) is divided into several components: (1) formulation, (2) separate layers -stratum corneum, viable epidermis, dermis, subcutaneous tissue, muscle, (3) hair follicle, and (4) local vasculature (blood circulation). The model accounts for longitudinal diffusion and distribution processes considering skin physiology related parameters (i.e. tortuosity of the diffusion pathway, keratin adsorption kinetics, stratum corneum (SC) hydration state, hair follicular transport, pH at the skin surface and within the SC layers, etc.) and drug/formulation specific parameters (i.e. ionization at the skin surface, lipophilicity, vehicle viscosity, etc.). The model accounts for variability in dermal physiology to simulate within-subject (multiple locations available) and between-subject variability, including the sex and age effect. Additionally MPML differentiates between various formulations beginning from simple solutions, through emulsions, pastes, and patches. The input parameters include in vitro measured formulation-specific information (i.e. in vitro release, number of micelles, viscosity etc.). Regardless of the formulation studied evaporation of the solvent can also be accounted for.
Age related changes to the physiology influence the ADME processes, and this includes disposition of drugs and other xenobiotics applied topically. The most commonly measured physiological properties of skin that influence the skin absorption are pH, skin and subcutaneous layers thickness and composition (amount and type of proteins and lipids as well as water content and their mutual ratios), local blood flow and the number of hair follicles. The MPML MechDermA PBPK model can be transformed into a model for dermal absorption in the older subjects based on parameter changes described below:
Skin surface pH
A meta-analysis of the skin surface pH data shows that in the volar forearm, neck and forehead there is a slight increase in this parameter in the elderly. However, measurement of pH at different areas of the back show a slight decrease in pH in elderly [71] [72] [73] [74] [75] [76] [77] [78] . This could influence the absorption rate in the elderly, based on the site of application of the drug formulation.
Skin thickness
Escoffier and co-workers reported that skin maintains its total thickness up to about 65 years and becomes thinner thereafter [79] . However, for predicting dermal absorption of compounds it is necessary to understand thickness of skin layers as summarized in Table 2 .
Blood flow
Comparison of adult and elderly blood flows shows no age related differences [76, 102, 103] .
Hair follicles
Sinclair and coworkers presented a linear regression with scalp hair follicles and age in subjects between 13 and 84 years old [104] . To our knowledge there are no reports that compare the number of hair follicles in different body sites between adults and elderly.
All the above mentioned parameters can influence the drug dermatopharmacokinetics [105] . Roskos and colleagues presented results of the study comparing permeation of various compounds: in the elderly compared with young individual [106] . According to their observations hydrophilic compounds (hydrocortisone, benzoic acid, acetylsalicylic acid, and caffeine) absorption was significantly lower, whereas lipophilic drugs behaviour (testosterone and estradiol) was not affected by age. Holdsworth et al. compared fentanyl disposition after a 24-h application of fentanyl transdermal patch in 10 healthy elderly subjects 67-87 years and 6 young subjects 19-27 years [107] . The observed higher serum concentrations reflect increased absorption and/or decreased clearance in the elderly. 5. An example of interplay between age, ethnicity and formulation leading to variable exposure
Bioequivalence studies are typically conducted in healthy volunteers. There has been a continuous discussion and debate on the necessity of conducting bioequivalence studies in the target population of patients (most of them being of older age). There are a variety of reasons, as outlined above, which makes the kinetics of the drug different in elderly populations. However, most of these would affect the drug regardless of the formulation. Hence, they may not be expected to have material impact on bioequivalence. The only exception is the impact of formulation during the absorption phase (whether oral or nonoral). The components of the formulation may introduce sensitivities to age-related attributes of the gastro-intestinal tract which leads to disparity between the drug products performance when they are compared with what happens in a healthy volunteer population. We describe such potential interplay combined with the effect of ethnic influence based on a recent report.
The case involves one formulation being influenced by achlorhydria to a much greater extent than the other. In a simulated comparison of the test and reference nifedipine controlled release formulations, the two formulations were shown to be bioequivalent in healthy volunteers (as observed in the clinical trial) but not in older Japanese subjects who have achlorhydria. Achlorhydric patients show elevated gastric pH which may lead to differential effects on various products of the same drug based on pH-sensitivity of the formulation. Doki et al. [108] examined the latter via PBPK simulations involving the mechanistic oral absorption model ADAM. The virtual bioequivalence (V-BE) studies highlighted the need for conduct of specific studies in elderly Japanese populations where there are discrepancies in pH-sensitivity of dissolution between the test and reference formulations.
Conclusions
The above discussions illustrate the utility of the application of PBPK models to predict the drug exposure resulting from different formulations and different routes of administration. Prediction of the differences in systemic drug exposure between young adults and older subjects can be used to inform clinical trial designs and highlight situations where dosage adjustments for the older subjects require consideration. PBPK models are not a substitute for the conduct of clinical studies in this population. However, they can highlight the possibility for discrepant bioequivalence or drug PK from those established in healthy volunteers and guide the conduct of clinical studies when there is adequate evidence for a likely difference. This approach may inform clinical testing during drug development, thus avoiding the conduct of logistically more difficult studies in the elderly in cases where they may not be needed.
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